Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

This study is testing a new three-drug combination — inobrodib, pomalidomide, and dexamethasone — in people with multiple myeloma (a type of blood cancer) that has come back or stopped responding to prior treatments. Inobrodib is a new type of drug called a p300/CBP bromodomain inhibitor, which works differently from existing myeloma therapies. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with multiple myeloma that has relapsed or not responded to your last treatment - You are in reasonably good physical health (ECOG 0–2) - Your blood counts, kidney function, and liver function are at acceptable levels - You are willing to use reliable contraception if sexually active **You may NOT be eligible if...** - You have received another investigational or cancer drug within the past 14 days (or 30 days for antibody therapies) - You have previously been treated with a p300/CBP bromodomain inhibitor - You have a known severe allergy to inobrodib, pomalidomide, dexamethasone, or related immunomodulatory drugs (e.g., lenalidomide, thalidomide) - You have had major surgery or a live vaccine within 4 weeks of starting the study - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.